

PATIENT SAFETY 101: PREVENTING INFECTIOUS DISEASE TRANSMISSION DURING BLOOD GLUCOSE MONITORING

Nicola Thompson, PhD & Melissa Schaefer, MD

Division of Healthcare Quality Promotion,

Centers for Disease Control and Prevention. Atlanta, GA

Annual Association of Clinical Chemistry Meeting & Convention

2011 Annual Point-of-Care Coordinators Forum

Atlanta, GA July 28, 2011

The findings and conclusions in this presentation are those of the author and do not necessarily represent the official position of the Centers for Disease Control and Prevention

*National Center for Emerging and Zoonotic Infectious Diseases
Division of Healthcare Quality Promotion*



Objectives

- ❑ List key factors that contribute to infection transmission during blood glucose monitoring and use of associated point of care devices
- ❑ Discuss best practices and current prevention recommendations for ensuring patient safety
- ❑ Evaluate the use of point of care devices, identify opportunities for infection transmission, and determine appropriate corrective action

Outline

- ❑ Background, bloodborne pathogen transmission during blood glucose monitoring
- ❑ HBV infection outbreaks during blood glucose monitoring
 - Recent outbreaks, patient notifications
- ❑ Prevention recommendations
- ❑ Recent federal prevention initiatives
 - CDC: Education, outreach
 - CMS: Inspection, enforcement
 - FDA: Device regulation


Features of bloodborne viruses relevant to healthcare transmission

Characteristic	HBV	HCV	HIV
# with chronic infection (U.S.) Millions	1.25	3.8	1.1
Titer (per ml)* * Blood, acute infection	10^{8-9}	10^6	10^{3-6}
Environmental stability	>week	days	hours
Infectivity (needlestick)	30%	~3%	~0.2%


Beltrami et al. Clin Micro Reviews, 2000.
 Bond et al. Lancet 1981; 8219:550-1.
 Shikata et al. J Infect Dis 1977;136:571-76.

MMWR 2001;50(No. RR-11).
 Kamilli et al. ICHE 2007; 28:519-524

Person-to-person transmission of bloodborne viruses during blood glucose monitoring



Person-to-person transmission of bloodborne viruses during blood glucose monitoring



Indirect contact transmission

- ❑ The transfer of an infectious agent (e.g., HBV) from one patient to another through
 - ❑ A contaminated intermediate object
 - blood glucose meter
 - reusable fingerstick devices
 - ❑ Or person
 - healthcare personnel hands

Indirect transmission of HBV during diabetes care

Stable in environment
for at least 7 days


High viral titer: virus
present in absence
of visible blood

Transmission via
contaminated
surfaces/equipment

Bond et al. Lancet 1981; 8219:550-1.
Shikata et al. J Infect Dis 1977;136:571-76.

Practices associated with HBV transmission during blood glucose monitoring

1. Use of fingerstick devices on multiple persons



2. Failure to clean and disinfect blood glucose testing meters between each use




3. Failure to change or use gloves, or perform hand hygiene between procedures

CDC. MMWR 2005;54:220-23.

www.cdc.gov/injectionsafety/providers/blood-glucose-monitoring_faqs.html

1. Sharing reusable fingerstick lancing devices



Non-disposable
end cap, blood
stained



2. Blood contamination of glucose meters



Photo courtesy of the Statewide Program for Infection Control and Epidemiology (SPICE) at the University of North Carolina



High prevalence of blood contamination on blood glucose meters

- ❑ Survey of 12 hospitals,
 - ❑ 609 blood glucose meters tested for presence of hemoglobin
- ❑ 30.2% (range 0 - 60.6%) meters had blood contamination
 - ❑ 48% in ICUs vs. 29% in non-ICUs
 - ❑ 31.4% for on-meter vs. 26.6% for off-meter test strip dosing
- ❑ Only 1 hospital cleaned meters between each patient use
 - ❑ 50% (6/12) no schedule for cleaning
- ❑ Hospital location, increased number of meter operators significantly associated with blood contamination

High frequency of blood glucose meter use

- Assessment of glucose meter usage data in 214 bed acute care hospital

	October, 2008
Total number tests performed	11,665
Number of blood glucose meters	37 (315 tests/meter)
Number of patients	803 (12.5 tests/patient)
% tests performed sequentially on different patients	79.8% (9310)
-Within 24 hours	99.9% (9302)
-Within 1 hour	60.9% (5664)
Time needed to clean/disinfect meter following manufacturers instructions	310 hours (1.93 FTE)

3. Hand hygiene, glove use

- ❑ Healthcare personnel hands can become contaminated with blood while performing blood glucose monitoring
 - Pricking the patient's finger
 - Handling the test strip
- ❑ Blood can be transferred back to the meter when handled to obtain reading
- ❑ If the meter is not cleaned and disinfected after use, blood remaining on the meter can be transferred to subsequent patients via healthcare personnel hands
- ❑ Numerous outbreaks have implicated this mechanism in the spread of HBV infections^{1,2}

1: CDC. *MMWR* 2005;54:220-223.

2: Thompson & Perz. *J Diabetes Sci Technol* 2009;3(2):283-288.

Surveys of routine practices when providing blood glucose monitoring

	Virginia, 2006 ¹	Florida, 2007 ²		3 States, 2008 ³
Setting, no. facilities	Assisted Living Facilities, 50	Assisted Living Facilities, 33	Nursing Homes, 15	Ambulatory Surgery Centers, 68
% using personal use fingerstick devices for >1 person	16%, (7/45)	17%, (3/17)	7%, (1/15)	21%, (11/53)
% did not clean/ disinfect shared blood glucose meters between each use	50%, (4/8)	71%, (5/7)	73%, (11/15)	32%, (17/53)

1. Patel et al. ICHE 2009;30:209-14.


2. Thompson et al. J Am Geriatrics Soc 2010;58:914-18.

3. Schaefer et al. JAMA 2010; 303:2273-79.

HBV infection outbreaks during blood glucose monitoring

Blood glucose monitoring and hepatitis transmission: A long history

- Insulin introduced in 1922
- Spring lancet “Schnepper” to sample blood from earlobe of patients
- 1923 unexplained jaundice in 26 patients^{1,2}
 - Schnepper used for multiple patients
 - Cleaned inconsistently between uses



1: Flaum et al. 1926. Actas Medica Scandinavica.
2: Schmid. Journal Gastro & Hepatology, 2001.

Two more historical examples

- ❑ 1938: Epidemic of jaundice in a diabetes clinic¹
 - ❑ 28 cases noted over 2 ½ years
 - ❑ Multiple patients attending for blood draws
 - ❑ Overcrowding of clinic considered important contributing factor to transmission
- ❑ 1945: Hepatitis outbreak among persons with diabetes in a hospital²
 - ❑ 63 cases noted over 2 years
 - ❑ Transmission via sharing of contaminated syringes used to draw blood for glucose monitoring

1:Graham. Lancet 1938;2, 1.

2: Droller. BMJ 1945;623-5.


Single case reports: HBV infection and blood glucose monitoring

- Female with diabetes diagnosed with acute HBV infection¹
 - Only risk identified sharing her capillary blood sampler with co-worker who had hypoglycemic episode
 - Co-worker found to have chronic HBV infection
- 75 y/o female with diabetes diagnosed with HBV/HDV co-infection, fatal²
 - All contacts tested negative for HBV
 - Only risk identified repeated fingersticks for blood glucose monitoring at outpatient facility

1: Stapleton, Lemon. JAMA 1985;22:3250.


2: Mendez et al. Am J Gastro 1991;86:895-7.

Outbreaks of HBV infection associated with blood glucose monitoring - 1990 to 2010, US




Thompson, Perz. *J Diabetes Sci Technol* 2009; 3:283-88. CDC unpublished data (2009-10).

Outbreaks of HBV infection associated with blood glucose monitoring - 1990 to 2010, US



Thompson, Perz. *J Diabetes Sci Technol* 2009; 3:283-88. CDC unpublished data (2009-10).

Outbreaks of HBV infection associated with blood glucose monitoring - 1990 to 2010, US



Thompson, Perz. *J Diabetes Sci Technol* 2009; 3:283-88. CDC unpublished data (2009-10).

International HBV infection outbreaks due to blood glucose monitoring

- France
- Canada
- United Kingdom – 2004-07, 5 outbreaks reported¹
- Germany
- Poland
- Netherlands
- Belgium
- Japan

1: Duffel et al. Epi & Infection 2011; 139, 327-335

Overview of recent outbreaks

- 7 HBV infection outbreaks identified 2009-10
 - All in residents of Assisted Living Facilities (ALFs) receiving blood glucose monitoring
 - 62 with new HBV infection
 - range 3 – 20/outbreak
- North Carolina outbreak¹
 - 8 acute HBV infections; 6 died
- 2 outbreaks occurred across multiple ALFs
 - BGM services provided by same Home Health Nursing Agency
 - Includes 1 person receiving AMBG at home

1: MMWR. 2011 / 60(06);182

Data from four epidemiologic studies conducted during HBV infection outbreak investigations due to blood glucose monitoring - US, 2009-2010

State	Receiving BGM		Not receiving BGM		Relative Risk (95% CI)
	Tested	Acute HBV infection (%)	Tested	Acute HBV infection (%)	
NC	15	8 (53.3%); 6 died	25	0 (0%)	27.6 (3.4- 275.1)
VA	5	3 (60%)	26	1 (3.8%)	15.6 (2.7 – 97.1)
VA	13	12 (92%)	75	2 (2.8%)	35 (8.7– 137)
FL	10	6 (60%)	38	1 (2.6%)	22.8 (3.0– 168.3)

Reported outbreaks: the tip of an iceberg

- Under-reporting of cases
 - Long incubation period for HBV (up to 6 months)
 - Most (50-70%) infections are asymptomatic
 - Many persons go undiagnosed
- Under-recognition of healthcare as a risk for viral hepatitis
 - Traditionally, thought to be rare events in the US
- Older adults have multiple healthcare exposures
 - Identification of a single healthcare encounter as the venue of transmission is difficult
- Under-investigation of cases
 - Limited resources at health department
 - Time consuming, expensive (patient notification, screening)

Assisted Monitoring of Blood Glucose (AMBG) and insulin administration


- ❑ Term introduced in response to safety concerns related to HBV infection outbreaks during blood glucose monitoring
- ❑ Where another person assists with or performs testing and insulin administration for multiple persons
- ❑ Settings where AMBG may occur:
 - ❑ Nursing homes
 - ❑ Assisted living facilities
 - ❑ Hospitals, clinics, physicians offices
 - ❑ Senior centers
 - ❑ Health fairs
 - ❑ Correctional facilities
 - ❑ Schools, camps, shelters

An emerging problem: New generation of devices



Multi-lancet
fingerstick device

Sharing of multi-lancet fingerstick devices reported as cause of HBV infection outbreak in Nursing Home¹



Multidose Insulin
Pens

Sharing of multidose insulin pens reported^{2,3}

1: Gotz et al. Eurosurveillance 2008;13:1-4

2: www.newsinferno.com/archives/3066

3. www.lcsun-news.com/cj_11670031

Recent adverse events

- ❑ 4 patient notification events due to receipt of blood glucose monitoring or insulin administration
 - ❑ Recommendation for bloodborne pathogen testing (HBV, HCV and HIV) to groups of individuals potentially exposed to another person's blood

Year, setting	Equipment misused	Length of misuse	Persons at risk
2008, Hospital	Insulin pen	7 months	908
2009, Hospital	Insulin pen	7 months	2114
2009, Community Health Center	Multi-lancet fingerstick device	6 months	283
2010, Health fair	Multi-lancet fingerstick device	1 day	64
Total at risk			3369

Texas Military Hospital 2009 – Insulin Pen Reuse

- ❑ Individual use insulin pens used on multiple patients
 - ❑ Needle changed, but insulin reservoir reused between patients
- ❑ Risk of blood backflow into insulin reservoir^{1,2}
- ❑ Error in use identified only after several months
- ❑ Failure to follow manufacturers recommendations for single patient use
 - ❑ Despite nurses receiving training when pens first introduced
 - ❑ No single patient use warning on pens

1. Floch et al . *Diabetes Care* 1998; 21: 1502–04
2. Sonoki et al; *Diabetes Care* 2001;24:303-4



The screenshot shows a Bloomberg news article. The header includes the Bloomberg logo and navigation links: 'Anywhere | Professional | Solutions | About' and a 'Try the Bloomberg' button. Below the header is a navigation bar with 'QUICK', 'NEWS', 'VIEW', 'MARKETS', 'PERSONAL FINANCE', 'TV', 'RADIO', and 'MORE'. The main headline is 'Army Hospital May Have Spread Disease With Shared Insulin Pens' by Tom Randall, dated March 19, 2009. The article text states that more than 2,000 people may have been put at risk of AIDS and hepatitis by sharing insulin pens and cartridges in two Army hospitals, according to the U.S. Food and Drug Administration. It also mentions a warning from the FDA against sharing disposable insulin shots after the William Beaumont Army Medical Center in El Paso, Texas, reported that 2,114 diabetic patients may be at risk due to incorrect procedures between 2007 and 2009.

FDA Alert: Risk of BBP from shared use of insulin pens

The screenshot shows the FDA website with the following elements:

- U.S. Department of Health & Human Services logo and URL: www.hhs.gov
- FDA U.S. Food and Drug Administration logo
- A-Z Index and Search bar
- Navigation menu: Home | Food | Drugs | Medical Devices | Vaccines, Blood & Biologics | Animal & Veterinary | Cosmetics | Radiation-Emitting Products | Tobacco Products
- Drugs section with options: Share, Email this Page, Print this page, Change Font Size
- Breadcrumb: Home > Drugs > Drug Safety and Availability > Postmarket Drug Safety Information for Patients and Providers
- Left sidebar menu:
 - Drug Safety and Availability
 - Postmarket Drug Safety Information for Patients and Providers
 - Drug Safety Information for Healthcare Professionals
 - Communications about Ongoing Safety Reviews
 - Early Communications About Ongoing Safety Reviews
 - Healthcare Professional Sheets
 - Public Health Advisories (Drugs)
- Main content area:
 - Information for Healthcare Professionals: Risk of Transmission of Blood-borne Pathogens from Shared Use of Insulin Pens**
 - FDA ALERT [03/19/2009]:** The FDA is issuing this alert to remind healthcare providers and patients that insulin pens and insulin cartridges* (see description below) are never to be shared among patients. Sharing of insulin pens may result in transmission of hepatitis viruses, HIV, or other blood-borne pathogens.
 - The FDA has received information that insulin pens may have been shared among numerous patients (two thousand or more) in one hospital in the United States from 2007-2009 (<http://www.wbamc.amedd.army.mil/>), and in a smaller number of patients in at least one other hospital. Although the disposable needles in the insulin pens were reportedly changed for each patient, there is still a risk of blood contamination of the pen reservoir or cartridge. Patients who were treated with insulin pens at the hospitals in question are being contacted by the hospitals, and are being offered testing for hepatitis and HIV. Some of the potentially exposed patients have reportedly tested positive for hepatitis C; however it is not known if the hepatitis infection occurred through insulin pen sharing, or if those who tested positive had previously undiagnosed hepatitis C.
 - The current instructions for use for all insulin pens already state that the pens are not to be shared among patients. The FDA reminds healthcare providers, healthcare facilities, and patients that each insulin pen (and each insulin pen cartridge) is intended for use by one patient only. Each insulin pen (and each insulin pen cartridge) should be used only once and then discarded.

www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm133352.htm

Prevention recommendations

CDC Recommended practices for preventing patient-to-patient transmission

- ❑ Diabetes care procedures and techniques
 - ❑ Single use, disposable lancets
 - ❑ Avoid shared equipment including glucose meters
- ❑ Hand hygiene
- ❑ Medical management (fingerstick frequency)
- ❑ Training and oversight

Best practices: Fingertick devices

- ❑ Reusable Devices: Lancet can be remove and replace after each use, device can be used more than once
- ❑ Some previously approved, marketed for multi-patient use
 - Failures to change the disposable component
 - Difficulties with cleaning and disinfection after use
 - Linked to multiple HBV infection outbreaks
- ❑ **Never** to be used for more than one person
- ❑ Single-use, disposable fingertick devices: disposable, prevent reuse through an auto-disabling feature
- ❑ When assisted monitoring of blood glucose performed, these devices should be used
- ❑ Safest for patients and provider; reduce needlestick injuries

www.cdc.gov/injectionsafety/blood-glucose-monitoring.html

Best practices: Blood glucose meters

- ❑ Whenever possible, blood glucose meters should be assigned to an individual patient and NOT be shared
- ❑ If blood glucose meters must be shared, the device should be cleaned and disinfected after every use, per manufacturer's instructions.
 - If the manufacturer does not specify how the device should be cleaned and disinfected then it should not be shared.

Best practices: Blood glucose meters

- ❑ FDA recently released guidance for manufacturers regarding appropriate products and procedures for cleaning and disinfection of blood glucose meters
 - ❑ *The disinfection solvent you choose should be effective against HIV, Hepatitis C, and Hepatitis B virus. Outbreak episodes have been largely due to transmission of Hepatitis B and C viruses. However, of the two, Hepatitis B virus is the most difficult to kill. Please note that 70% ethanol solutions are not effective against viral bloodborne pathogens and the use of 10% bleach solutions may lead to physical degradation of your device.*

One hospital's experience with dedicating meters to individual patients

- ❑ Augmented glucose meter inventory from 38 to 115 throughout the hospital and assigned meter to individual patients on 3 high-use units
- ❑ Because of dedicated meters, time required for cleaning and disinfection of meters between patients reduced by 176 hours or 1.0 full-time equivalent
 - Offset cost for augmentation of the glucose meter inventory

Best practices: Insulin administration

- ❑ Insulin Pens: Safe for single person use multiple times, new needle for each injection
- ❑ Should be assigned to individual persons, labeled
- ❑ Should **never** be used for more than one person
- ❑ Insulin Vials: Multi-dose vials should be dedicated to single person whenever possible
- ❑ If used for >1 person, store and prepared in a dedicated area away from potentially contaminated equipment
- ❑ Vials **always entered** with new needle and new syringe
- ❑ Needles and syringes should **never** be used to administer insulin to >1 person
 - ❑ Disposed of immediately after use in approved sharps container

Best practices: Hand hygiene and glove use

- ❑ Hand Hygiene: Hand washing with soap and water or use of an alcohol-based hand rub
- ❑ Gloves: Wear gloves during blood glucose monitoring and during any other procedure that involves potential exposure to blood or body fluids
- ❑ Change gloves between patient contacts or that have touched potentially blood-contaminated objects or fingerstick wounds **before** touching clean surfaces
- ❑ Discard gloves in appropriate receptacles
- ❑ Perform hand hygiene immediately after removal of gloves and before touching other medical supplies intended for use on other persons

Best practices: Training and oversight

- ❑ Provide hepatitis B vaccination series to previously unvaccinated staff with activities involving blood or body fluids
- ❑ Establish responsibility for oversight of infection control activities
 - ❑ Provide staff members with infection control training
 - ❑ Periodically observe staff to assess adherence to infection control recommendations
- ❑ Report to public health authorities any suspected instances of a newly acquired bloodborne infection, such as hepatitis B, in a patient, facility resident, or staff member

Recent federal prevention initiatives

CDC: Communication, prevention activities - I

- Since Jan 2009, 7 CDC-authored publications
- Highlight need for improved
 - Awareness of risks
 - Adherence to infection control recommendations
 - Enforcement of infection control recommendations
 - Improvements in device design/labeling, use of engineering controls
- CDC organized/hosted meetings (9/2009, 5/2010) to raise awareness of the needs for improved infection control oversight and device regulation¹
 - Key federal partners (CMS and FDA)
 - Other stakeholders including device manufacturers, diabetes educators, health departments

1: www.cdc.gov/injectionsafety/meetings/stickingVsafety52010.html

CDC: Communication, prevention activities - II

- Issued clinical reminder

CDC CLINICAL REMINDER

Use of Fingerstick Devices on More than One Person Poses Risk for Transmitting Bloodborne Pathogens

Summary: The Centers for Disease Control and Prevention (CDC) has become increasingly concerned about the risks for transmitting hepatitis B virus (HBV) and other bloodborne pathogens to persons undergoing fingerstick procedures for blood sampling -- for instance, persons with diabetes who require assistance monitoring their blood glucose levels. Reports of HBV infection outbreaks linked to diabetes care have been increasing^{1,2,3}. This notice serves as a reminder that fingerstick devices should never be used for more than one person.

Background

Fingerstick devices are devices that are used to prick the skin and obtain drops of blood for testing. There are two main types of fingerstick devices: those that are designed for reuse on a single person and those that are disposable and for single-use.



- **Reusable Devices:** These devices often resemble a pen and have the means to remove and replace the lancet after each use, allowing the device to be used more than once (see **Figure 1**). Due to difficulties with cleaning and disinfection after use and their link to numerous outbreaks, CDC recommends that these devices never be used for more than one person. If these devices are used, it should only be by individual persons using these

www.cdc.gov/injectionsafety/Fingerstick-DevicesBGM.html

CDC: Communication, prevention activities - III

- ❑ Updated infection control guidance¹
 - ❑ Fingertick devices should never be used for more than one person
 - ❑ In settings where *assisted* monitoring of blood glucose is performed, single-use, auto-disabling fingertick devices should be used
 - ❑ Whenever possible, blood glucose meters should be assigned to an individual person and not be shared
 - ❑ If blood glucose meters must be shared, the device should be cleaned and disinfected after every use

Best Practices for Assisted Blood Glucose Monitoring and Insulin Administration

The following are infection control recommendations that anyone who performs or assists with blood glucose monitoring and/or insulin administration should review to assure they are not placing themselves or persons in their care at risk.

These recommendations apply not only to licensed healthcare facilities but also to any setting where fingertick procedures are performed and/or insulin is administered, including assisted living or residential care facilities, clinics, health fairs, shelters, detention facilities, schools, and camps. Protection from bloodborne viruses and other infections is a basic requirement and expectation anywhere healthcare is provided.

[Top of page](#) ↑

Fingertick Devices

Fingertick devices, also called lancing devices, are devices that are used to prick the skin and obtain drops of blood for testing. There are two main types of fingertick devices: those that are designed for reuse on a single person and those that are disposable and for single-use.

- **Reusable Devices:** These devices often resemble a pen and have the means to remove and replace the lancet after each use, allowing the device to be used more than once. Some of these devices have been previously approved and marketed for multi-patient use, and require the lancet and disposable components (platforms or endcaps) to be changed between each patient. However, due to failures to change the disposable components, difficulties with cleaning and disinfection after use, and their link to multiple HBV infection outbreaks, CDC recommends that these devices **never** be used for more than one person. If these devices are used, it should only be by individual persons using these devices for self-monitoring of blood glucose.



- **Single-use, auto-disabling fingertick devices:** These are devices that are disposable and prevent reuse through an auto-disabling feature. In settings where assisted monitoring of blood glucose is performed, single-use, auto-disabling fingertick devices should be used.



A simple rule for safe care:
Fingertick devices should **never** be used for more than one person.

1: www.cdc.gov/injectionsafety/blood-glucose-monitoring.html

CDC: Communication, prevention activities - III

- ❑ Frequently asked questions regarding AMBG¹
 - ❑ General
 - ❑ Fingerstick devices
 - ❑ Blood glucose meters
 - ❑ Insulin pens

Frequently Asked Questions (FAQs) regarding Assisted Blood Glucose Monitoring and Insulin Administration

Background

The following FAQs summarize inquiries from healthcare personnel received by CDC regarding best practices for performance of assisted blood glucose monitoring and insulin administration, including questions related to cleaning, disinfection, and storage of blood glucose monitoring equipment.

These FAQs are not intended as a comprehensive resource for all issues related to blood glucose monitoring, and insulin administration and additional considerations may be necessary for certain clinical situations or settings. [View more detailed information](#) related to assisted blood glucose monitoring and insulin administration. Visit [CDC's Injection Safety website](#) for additional information regarding injection safety and [CDC's Sharps Safety website](#) information related to sharps safety and safe disposal of sharps in healthcare settings.


Healthcare personnel are also encouraged to consult guidance provided by the Food and Drug Administration (FDA) (links provided in responses below) as well as the manufacturers of the devices (blood glucose meters, fingerstick/lancing devices, insulin pens) in use at their facilities.

On this Page

- General
- Fingerstick/Lancing Devices
- Blood Glucose Meters
- Insulin Pens and Insulin Administration
- References

FDA: Communication, device evaluation

- ❑ FDA issued Medical Device Alert for point of care blood testing devices¹



- ❑ FDA notice to manufacturers of revised process for evaluating, approving blood glucose monitoring devices, and increased focus on addressing infection prevention²
 - ❑ To include clear labeling of single patient use, validated instructions for cleaning/disinfecting meters

1: www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm224025.htm

2: www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm227935.htm

CMS: Regulatory activities

- ❑ CMS issued new infection control guidance to surveyors who conduct facility inspections
 - ❑ Includes review of blood glucose monitoring practices at Nursing Homes and Ambulatory Surgery Centers
- ❑ For nursing homes, directive specifies that sharing of fingerstick devices must be cited as Immediate Jeopardy
 - ❑ Requires immediate steps to remove the jeopardy from the Nursing Home or risk termination from Medicare/Medicaid programs
- ❑ Guidance is carrying over to other licensed settings
 - ❑ Acute care hospitals, home health agencies

Summary - I

- ❑ Shared use of blood contaminated equipment increases risk of exposure to bloodborne pathogens
- ❑ Increasing frequency of HBV infection outbreaks associated with Assisted Monitoring of Blood Glucose
- ❑ Routine misuse of equipment, failure to follow infection control recommendations identified in a variety of settings
 - ❑ Acute care hospitals, ambulatory surgery centers, health fairs

Summary - II

- Continued efforts needed to
 - Increase adherence to recommended infection control practices
 - Improve device labeling, instructions for use, cleaning and disinfection guidance
- Recent changes made by CMS and FDA are expected to aid adoption of recommendations
- Prevention in settings such as assisted living facilities remains challenging
 - Standardized training and education, oversight needed

Prevention in assisted living facilities

- Remains challenging
 - Operate under a social model of care
 - Care primarily provided by non-professional staff, limited professional oversight
 - Resources, expertise in infection control is poor
 - Staff turn-over very high, limits impact of education/training efforts
- ALFs not federally regulated
 - Licensing, inspection at state level highly variable
 - Outside the scope of CMS; however, home health agencies are regulated by CMS

Assisted Living

- Group living arrangement, in home-like environment
- Developed partially in response to consumer dissatisfaction with nursing homes as a place to live
- Provide residents help with activities of daily living , medication administration includes Assisted Monitoring of Blood Glucose
- Currently, ~1 million residents
- Estimated , ~2 million residents by 2030

Assisted Living State Regulatory Review 2010: www.ahcancal.org